FDA Expands Organon TOFIDENCE Approval to 2 New Uses, Including COVID-19
Updated
Updated · Simply Wall St · Jun 13
FDA Expands Organon TOFIDENCE Approval to 2 New Uses, Including COVID-19
2 articles · Updated · Simply Wall St · Jun 13
Summary
Organon won an FDA label expansion for TOFIDENCE, adding treatment of severe cytokine release syndrome and certain hospitalized COVID-19 patients.
The decision broadens the market for Organon’s tocilizumab biosimilar and adds to its recent push in higher-margin biosimilars.
Shares traded around $13.44 after the news; the stock has surged 111.65% over 90 days and 85.64% year to date.
That rally contrasts with a 27.03% decline in total shareholder return over three years, underscoring how recent momentum has followed a longer weak stretch.
Even after the approval, Simply Wall St said the most-followed valuation narrative pegs fair value at $11.25—about 20% below the current price.